New drug combo may shrink throat tumors and allow gentler treatment

NCT ID NCT07290621

First seen Jan 11, 2026 · Last updated May 14, 2026 · Updated 20 times

Summary

This study tests whether giving the immunotherapy drug toripalimab with chemotherapy before standard treatment can shrink HPV-related throat cancer tumors by at least half. About 30 people with advanced HPV16-positive oropharyngeal cancer will receive the drug combo, then either robotic surgery or reduced-intensity radiation based on how well the tumor responded. The goal is to see if this approach can reduce the need for aggressive treatment while still controlling the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OROPHARYNGEAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The University of Chicago Medicine Comprehensive Cancer Center

    RECRUITING

    Chicago, Illinois, 60637, United States

    Contact Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.